LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a developer, manufacturer and marketer of the EVO family of implantable collamer lenses (ICL) for myopia, astigmatism and presbyopia, has announced that preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million, with U.S. ICL sales expected to be $5 million for the quarter. This represents the company’s highest quarterly ICL sales in the U.S. since the company obtained U.S. FDA approval of the EVO ICL in March 2022, according to the announcement.

“STAAR is off to a solid start in 2024, as illustrated by our preliminary first quarter results, including a record quarter in the U.S.,” said Tom Frinzi, president and CEO of STAAR Surgical. “U.S. ICL sales were up approximately 20 percent sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus. EMEA ICL sales were up approximately 11 percent year over year and ICL sales in our APAC region were up approximately 9 percent, including approximately 10 percent growth in China.

"We are pleased by the first quarter performance across all major geographies and will provide further detail on our results and outlook during our upcoming earnings call, but at this time we believe our fiscal 2024 net sales can be at the higher end of our previously announced outlook range of $335 million to $340 million.”

Cash, cash equivalents and investments available for sale was approximately $248 million, and accounts receivable was approximately $70 million as of March 29, 2024, as compared with $232.4 million and $94.7 million, respectively, at December 29, 2023, according to the announcement. The company expects to report complete first quarter financial results and discuss its fiscal 2024 outlook during its quarterly earnings call on or about May 8, 2024.